Helen Torley Halozyme Therapeutics, Inc. (HALO) insider trading activity

Helen Torley is PRESIDENT AND CEO of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 666,744 shares of HALO, which is worth approximately $31.4 Million. The most recent transaction as insider was on Sep 07, 2021, when has been sold 50,000 shares (Common Stock) at a price of $14.66 per share, resulting in proceeds of $733,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 667K

1.48% 3M change

6.91% 12M change

Total Value Held $31.4 Million

Helen Torley Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 07 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 7.85%	587,160 Common Stock
Aug 10 2021	SELL Open market or private sale	$2,157,000 $43.14 p/Share	50,000 Reduced 8.52%	537,160 Common Stock
Aug 10 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 7.85%	587,160 Common Stock
Jul 06 2021	SELL Open market or private sale	$2,298,500 $45.97 p/Share	50,000 Reduced 8.52%	537,160 Common Stock
Jul 06 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 7.85%	587,160 Common Stock
Jun 07 2021	SELL Open market or private sale	$1,983,000 $39.66 p/Share	50,000 Reduced 8.52%	537,160 Common Stock
Jun 07 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 7.85%	587,160 Common Stock
May 11 2021	SELL Open market or private sale	$2,177,000 $43.54 p/Share	50,000 Reduced 8.52%	537,160 Common Stock
May 11 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 7.85%	587,160 Common Stock
Apr 05 2021	SELL Open market or private sale	$2,127,500 $42.55 p/Share	50,000 Reduced 8.52%	537,160 Common Stock
Apr 05 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 7.85%	587,160 Common Stock
Mar 01 2021	SELL Open market or private sale	$2,301,500 $46.03 p/Share	50,000 Reduced 8.52%	537,160 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 7.85%	587,160 Common Stock
Feb 22 2021	SELL Payment of exercise price or tax liability	$949,991 $48.69 p/Share	19,511 Reduced 3.5%	537,160 Common Stock
Feb 22 2021	BUY Exercise of conversion of derivative security	-	39,354 Added 6.6%	556,671 Common Stock
Feb 14 2021	SELL Payment of exercise price or tax liability	$709,871 $49.84 p/Share	14,243 Reduced 2.68%	517,317 Common Stock
Feb 14 2021	BUY Exercise of conversion of derivative security	-	28,729 Added 5.13%	531,560 Common Stock
Feb 12 2021	SELL Payment of exercise price or tax liability	$810,349 $49.84 p/Share	16,259 Reduced 3.13%	502,831 Common Stock
Feb 12 2021	BUY Exercise of conversion of derivative security	-	32,795 Added 5.94%	519,090 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$784,755 $50.6 p/Share	15,509 Reduced 3.09%	486,295 Common Stock
Feb 10 2021	BUY Exercise of conversion of derivative security	-	31,282 Added 5.87%	501,804 Common Stock
Feb 01 2021	SELL Open market or private sale	$2,406,500 $48.13 p/Share	50,000 Reduced 9.61%	470,522 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	$733,000 $14.66 p/Share	50,000 Added 8.76%	520,522 Common Stock
Nov 30 2020	SELL Bona fide gift	-	10,000 Reduced 2.08%	470,522 Common Stock
Nov 25 2020	SELL Open market or private sale	$2,033,500 $40.67 p/Share	50,000 Reduced 9.42%	480,522 Common Stock

Also insider at

DGX

QUEST DIAGNOSTICS INC Healthcare

Director

Helen Torley

PRESIDENT AND CEO

Secaucus, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Value

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

Operation

Value

Type

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO

Account